Reply to 'F508del-CFTR is not corrected by thymosin α1'.

Plain Language Summary

This article is a published reply addressing a correspondence about whether thymosin alpha-1 can correct the F508del-CFTR defect in cystic fibrosis. The exchange represents an ongoing scientific debate about the therapeutic potential of thymosin alpha-1 for treating the underlying protein defect in CF.